In a phase 1 3+3 dose-escalation study, NCT03281824, patients with HER2-positive breast cancer who had been treated very heavily with a minimum of two rounds of anti-HER2 therapy were considered for this trial. This evidence concerns the gene ERBB2 and breast carcinoma.